Citigroup Upgrades Editas Medicine to Buy, Announces $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow has upgraded Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announced a price target of $11.
October 24, 2023 | 10:21 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup analyst Samantha Semenkow has upgraded Editas Medicine to Buy and set a price target of $11.
While Citigroup's actions can influence the market, this specific news is more about their analysis of Editas Medicine rather than a direct impact on Citigroup's own stock. Therefore, the short-term impact on Citigroup's stock is likely neutral.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Editas Medicine has been upgraded from Neutral to Buy by Citigroup with a price target of $11.
The upgrade from Neutral to Buy by Citigroup indicates a positive outlook for Editas Medicine. The price target of $11 suggests that the analyst sees potential for the stock's price to increase. This could lead to a positive short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100